All results
2 results for phase 2 multi center double blind randomized dose ranging placebo controlled study
-
IMPALA-2
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Vasomune AV001-004
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…
- Ages
- 18 Years - N/A
- Sexes
- All